Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	733030-01-8
Formula :	C₁₉H₂₃Cl₂F₃N₆O₇
M.W :	575.32
SMILES Code :	O=C1N(C=C(C(N1)=O)C(F)(F)F)[C@H]2C[C@@H]([C@H](O2)CO)O.O=C3NC(CN4CCCC4=N)=C(C(N3)=O)Cl.Cl[H]
Synonyms :	TAS-102; FTD/TPI; TAS102, TAS-102, TAS 102, Trifluridine/tipiracil hydrochloride
MDL No. :	MFCD30481309

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

HT29 cells	0, 1, 4, 8 μM	24, 48, 72 hours	FTD/TPI inhibits the viability and proliferation of HT29 cells in a dose-dependent manner	PMC11972347
DLD1 cells	0, 1, 4, 8 μM	24, 48, 72 hours	FTD/TPI inhibits the viability and proliferation of DLD1 cells in a dose-dependent manner	PMC11972347
HCT116	5 µM(IC50)	72 h	Evaluate the effect of AZD6738 combined with FTD on HCT116 cell viability. Results showed that AZD6738 combined with FTD significantly inhibited cell viability.	PMC9926513
HT29	70 µM(IC50)	72 h	Evaluate the effect of AZD6738 combined with FTD on HT29 cell viability. Results showed that AZD6738 combined with FTD significantly inhibited cell viability.	PMC9926513
CRC and PDAC p53Mut cell lines	0.5 μM	24-72 h	Evaluate DNA damage response to TAS102 in p53Mut cells, showing accumulation of DNA damage marker (γH2AX).	PMC10982975
HCT116 p53KO	0.5 μM	24-72 h	Evaluate DNA damage response to TAS102 in p53-deficient cells, showing accumulation of DNA damage (γH2AX).	PMC10982975
HCT116 p53WT	0.5 μM	24-72 h	Evaluate DNA damage response to TAS102 in p53WT cells, showing transient activation of p53-p21 axis and increase in DNA damage marker (γH2AX).	PMC10982975
iPSC-derived VSMCs (from HGPS patients)	5 µM	48 h	To screen compounds that can increase NAD+ levels. Results showed that Trifluridine significantly increased NAD+ levels by inhibiting PARP-1 activity and improved cell viability.	PMC11448498
VSMCs from LmnaG609G/G609G mice	5 µM	48 h	To evaluate the effect of Trifluridine on NAD+ levels and cell viability. Results showed that Trifluridine significantly increased NAD+ levels by inhibiting PARP-1 activity and improved cell viability.	PMC11448498
HT29 cells	0-16 μM	24-72 h	FTD/TPI inhibited the viability and proliferation of HT29 cells in a dose- and time-dependent manner.	PMC11972347
DLD1 cells	0-16 μM	24-72 h	FTD/TPI inhibited the viability and proliferation of DLD1 cells in a dose- and time-dependent manner.	PMC11972347
HCT116 cells	0-16 μM	24-72 h	FTD/TPI inhibited the viability and proliferation of HCT116 cells in a dose- and time-dependent manner.	PMC11972347
RKO cells	0-16 μM	24-72 h	FTD/TPI inhibited the viability and proliferation of RKO cells in a dose- and time-dependent manner.	PMC11972347

BALB/cSlc-nu/nu mice	Esophageal squamous cell carcinoma xenograft model	Oral	200 mg/kg	Once daily for 3 weeks (TE-8) or 4 weeks (PDX)	To evaluate the antitumor effect of FTD/TPI and MK1775 combination therapy on esophageal squamous cell carcinoma xenograft models. Results showed that the combination therapy significantly suppressed tumor growth and increased γ-H2AX expression, indicating increased DNA double-strand breaks.	PMC10728021
NPG mice	Patient-derived xenograft models	Intraperitoneal injection	150 mg/kg	Once daily for 5 days as the first round, followed by a second round after a 2-day break	Combination therapy of FTD/TPI and SAS significantly inhibited tumor growth, reducing tumor volume and weight	PMC11972347
NPG mice	Patient-derived xenograft (PDX) models	Intraperitoneal injection	150 mg/kg	Once daily for 5 days as one round, total two rounds	Combination therapy of FTD/TPI and SAS significantly inhibited tumor growth in PDX models, reducing tumor volume and weight.	PMC11972347
BALB/c nu/nu mice	HT29 xenograft model	Oral	200 mg/kg	Twice daily, 6-hour interval, for 3 weeks (5 days dosing, 2 days rest)	Evaluate the inhibitory effect of TAS-102 combined with AZD6738 on tumor growth in HT29 xenograft model. Results showed that the combination significantly inhibited tumor growth.	PMC9926513
Nude mice (BALB/cAJcl-nu/nu)	HCT116 p53-KO, p53-R175H, and p53-R248Q xenograft models	Oral	200 mg/kg	Once daily, days 1-5 and 8-12	To evaluate the anti-tumor effect of FTD/TPI on p53-GOF mutant xenografts, showing significant tumor growth suppression independent of p53 status.	PMC11219725
Mice	LmnaG609G/G609G mouse model	Oral	150 mg/kg	Once daily for 4 weeks	Trifluridine treatment was able to alleviate aortic VSMCs loss and improve clinical signs of progeria.	PMC11448498
Nude mice	Human colorectal cancer xenograft model	Oral	150 mg/kg	Twice daily for 14 days	To evaluate the antitumor effects of TAS-102 in combination with bevacizumab, cetuximab, or panitumumab. Results showed that the combination of TAS-102 and bevacizumab was significantly more effective than monotherapy in SW48 and HCT116 tumor models, with higher concentrations of phosphorylated FTD in tumors.	PMC4391594
SCID/CB17 mice	HT29 and MIAPACA2 tumor xenograft models	Oral gavage	50 mg/kg	5 days on, 2 days off	Evaluate anti-tumor efficacy of TAS102 combined with PARPi, showing significant inhibition of p53Mut tumor growth and extended survival.	PMC10982975
BALB/c mice	Colon cancer model	Oral	150 mg/kg	Once daily for 5 days	To evaluate the cytotoxic and pharmacodynamic effects of TAS-102 in vivo on colon cancer cells. Results showed TAS-102 significantly inhibited the growth of both cell lines (50%, P<0.01) and induced G2M-phase arrest and apoptosis.	PMC2360204
Nude mice	Subcutaneous implantation model	Oral	15 mL/kg	Once a day for 1 week	Evaluate the antitumor effect of FTD on pancreatic cancer, results showed that the tumor volume increase was suppressed in the FTD group	PMC6981298
SCID mice	LIM1215 and COL-01-JCK colon cancer patient-derived xenograft models	Orally	75 mg/kg	Twice daily for 2 weeks	To evaluate the in vivo antitumor effects of panitumumab and TAS-102 combination. Results showed that combination treatment caused significant tumor regression in LIM1215 and COL-01-JCK models.	PMC5537908
SCID/CB17 mice	MDA-MB-231 xenograft model	Oral gavage	50 mg/kg	5 days on, 2 days off	To evaluate the anti-tumor efficacy of TAS102 combined with PARP inhibitor, results showed significant inhibition of tumor growth and metastasis	PMC8275734
LmnaG609G/G609G mice	HGPS mouse model	Oral	150 mg/kg	Once daily for 4 weeks	To evaluate the effect of TAS-102 on aortic VSMCs loss and HGPS phenotype. Results showed that TAS-102 significantly reduced VSMCs loss and improved aortic disease phenotype.	PMC11448498

{[proInfo.proName]}

CAS No.: 733030-01-8

{[proInfo.proName]}

CAS No.: 733030-01-8

Alternative Products

Product Details of Trifluridine/tipiracil HCl mixture

Safety of Trifluridine/tipiracil HCl mixture

Related Pathways of Trifluridine/tipiracil HCl mixture

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT05343013	Colorectal Cancer	PHASE2	SUSPENDED	2025-05-15	MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less <<
NCT04627961	Metastatic Nasopharyngeal Carc... More >>inoma\|Recurrent Nasopharyngeal Carcinoma Less <<	PHASE2	UNKNOWN	2025-10-24	National University Hospital, ... More >>Singapore, Singapore Less <<
NCT02301117	Advanced Solid Tumors	PHASE1	COMPLETED	2019-06-19	Phoenix Clinical Site, Phoenix... More >>, Arizona, 85054, United States\|Duarte Clinical Site, Duarte, California, 91010, United States\|Santa Monica Clinical Site, Santa Monica, California, 90095, United States\|Gainesville Clinical Site, Gainesville, Florida, 32610, United States\|Baltimore Clinical Site, Baltimore, Maryland, 21231, United States\|Boston Clinical Site, Boston, Massachusetts, 02111, United States\|Cleveland Clinical Site, Cleveland, Ohio, 44106, United States\|Cleveland Clinical Site, Cleveland, Ohio, 44195, United States\|Pittsburgh Clinical Site, Pittsburgh, Pennsylvania, 15232, United States\|Dallas Clinical Site, Dallas, Texas, 75246, United States\|Brno Clinical Site, Brno, Czechia\|Praha Clinical Site, Praha, Czechia\|Belgrade Clinical Site, Belgrade, 11080, Serbia\|Sremska Kamenica Clinical Site, Sremska Kamenica, 21204, Serbia Less <<
NCT02921737	Pancreatic Cancer	PHASE2	TERMINATED	2020-07-26	Malcom Randall VA Medical Cent... More >>er, Gainesville, Florida, 32608, United States\|UF Health Cancer Center, Gainesville, Florida, 32608, United States\|Tallahasee Memorial HealthCare, Tallahassee, Florida, 32308, United States Less <<
NCT02261532	Advanced or Metastatic Solid T... More >>umors Less <<	PHASE1	COMPLETED	2025-06-17	Taiho Pharmaceutical Co., Ltd ... More >>selected site, Beijing, China Less <<
NCT02286492	Colorectal Cancer Metastatic		APPROVED_FOR_MARKETING	-	Alabama Oncology, Birmingham, ... More >>Alabama, 35211, United States\|Mayo Clinic, Scottsdale, Arizona, 85259, United States\|California Cancer Associates for Research and Excellence, Fresno, California, 93720, United States\|Global Cancer Research Institute (GCRI), Inc., Gilroy, California, 95020, United States\|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States\|Pacific Hematology Oncology Associates (PHOA), San Francisco, California, 94115, United States\|Rocky Mountain Cancer Center, Denver, Colorado, 80218, United States\|Yale Cancer Center, New Haven, Connecticut, 06520, United States\|Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, 20007, United States\|University of Florida Health Davis Cancer Center, Gainesville, Florida, 32610, United States\|Ocala Oncology Center, Ocala, Florida, 34471, United States\|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States\|The University of Chicago, Chicago, Illinois, 60637, United States\|Illinois CancerCare, P.C., Peoria, Illinois, 61615-7828, United States\|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States\|University of Michigan Hospital, Ann Arbor, Michigan, 48109, United States\|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States\|Mayo Clinic, Rochester, Minnesota, 55905, United States\|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States\|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States\|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08901, United States\|University of Rochester, Rochester, New York, 14642, United States\|Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, United States\|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States\|The Mark H. Zangmeister Center, Columbus, Ohio, 43219, United States\|Hematology and Oncology Associates of Northeastern Pennsylvania, Dunmore, Pennsylvania, 18512, United States\|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States\|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States\|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States\|Texas Oncology Sammons Cancer Center, Dallas, Texas, 75246, United States\|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States\|Fox Valley Hematology & Oncology, Appleton, Wisconsin, 54915, United States Less <<
NCT02920476	Squamous Cell Lung Carcinoma	PHASE2	COMPLETED	2021-08-14	UF Health Cancer Center, Gaine... More >>sville, Florida, 32608, United States Less <<
NCT02301104	Advanced Solid Tumors	PHASE1	COMPLETED	2025-06-16	Mayo Clinic, Scottsdale, Arizo... More >>na, 85259, United States\|Duarte Clinical Site, Duarte, California, 91010, United States\|Santa Monica Clinical Site, Santa Monica, California, 90404, United States\|Baltimore Clinical Site, Baltimore, Maryland, 21231, United States\|Boston Clinical Site, Boston, Massachusetts, 02111, United States\|Cleveland Clinical Site, Cleveland, Ohio, 44195, United States\|Pittsburgh Clinical Site, Pittsburgh, Pennsylvania, 15232, United States\|Dallas Clinical Site, Dallas, Texas, 75246, United States Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed